Targeting epidermal growth factor receptor: Novel therapeutics in the management of cancer

Expert Review of Anticancer Therapy

Volumn 3, Issue 3, 2003, Pages 367-380

  Khalil, Mazen Y ^a   Grandis, Jennifer R ^b   Shin, Dong M ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b University of Pittsburgh School of Medicine   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

antiEGRF mABs; EGFR; ErbB; TKIs; Tyrosine kinase

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; CANERTINIB; CETUXIMAB; CISPLATIN; CPG 59236; DOXORUBICIN; EMD 55900; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; H R3; H22 EGF; ICR 62; IRINOTECAN; LAPATINIB; MDX 447; MONOCLONAL ANTIBODY; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PACLITAXEL; PANITUMUMAB; PD 160678; PD 165557; PROTEIN TYROSINE KINASE INHIBITOR; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; COLON CANCER; DIARRHEA; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; EYE TOXICITY; FEVER; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; LUNG CANCER; MOUSE; NAUSEA; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; RASH; REVIEW; SKIN MANIFESTATION; VOMITING;

EID: 0037531643     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.3.367     Document Type: Review

References (140)

1. Fedi P, Pierce JH, Di Fiore PP et al. Efficient coupling with phosphatidylinositol Cγ or GTPase-activating protein distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol. Cell Biol. 14, 492-500 (1994).
2. Earp HS, Dawson TL, Li X et al. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat. 35(1), 115-132 (1995).
3. Salomon DS, Brand R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183-232 (1995).
4. Walker R. The ErbB/HER Type 1 tyrosine kinase receptor family. J. Pathol. 185, 234-235 (1998).
5. Prigent SA, Lemoine NR. The Type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog. Growth Factor Res. 4, 1-24 (1992).
6. Yokota J, Yamamoto T, Toyoshima K et al. Amplifications of C-ErbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1, 765-767 (1986).
7. Lemoine NR, Barnes DM, Hollywood DP et al. Expression of the ErbB3 gene product in breast cancer. Br. J. Cancer 66 116-1121 (1992).
8. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull. 47, 87-98 (1991).
9. Ezeh P, Farbman A. Differential activation of ErbB receptors in the rat olfactory mucosa by transforming growth factor-α and epidermal growth factor in vivo. J. Neurobiol. 37, 199-210 (1998).
10. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Ann. Rev. Biochem. 57, 443-478 (1998).
11. Brandt R, Eisenbrandt R, Leenders F et al. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation. Oncogene 19, 2129-2137 (2000).
12. Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest. 9, 553-562 (1991).
13. Yao M, Shuin T, Misaki H et al. Enhanced expression of c-myc and epidermal growth factor receptor (C-ErbB-1) genes in primary human renal cancer. Cancer Res. 48, 6753-6757 (1998).
14. Harris AL, Nicholson S, Sainsbury JR et al. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J. Steroid Biochem. 34, 123-131 (1989).
15. Fox SB, Smith K, Hollyer J et al. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat. 29, 41-49 (1994).
16. Lamerz R. Role of tumor markers, cytogenetics. Ann. Oncol. 10, 145-149 (1999).
17. Sainsbury JR, Farridon JR, Needham GK et al. Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1, 1398-1402 (1987).
18. Klijn JG, Look MP, Portengen H et al. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer. results of a 10 year follow-up study. Breast Cancer Res. Treat. 29, 73-83 (1994).
19. Ohsaki Y, Tanno S, Fujita Y et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol. Rep. 7, 603-607 (2000).
20. Hurtt MR, Mossy J, Donovan-Peluso M et al. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J. Neuropathol. Exp. Neurol. 51, 84-90 (1992).
21. Veale D, Ashcroft T, Marsh C et al. Epidermal growth factor receptors in non-small cell lung cancer. Br. J. Cancer 55, 513-516 (1987).
22. Yamanaka Y. The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-ErbB-2 oncoprotein in human pancreatic cancer. J. Nippon. Med. Sch. 59, 51-61 (1992).
23. Dong M, Nio Y, Guo KJ et al. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res. 18, 4613-4619 (1998).
24. Krupski T, Moskaluk C, Boyd JC et al. A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder. BJU Int. 85, 1027-1032 (2000).
25. Nguyen PL, Swanson PE, Jaszcz W et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder: a multivariate survival analysis. Am. J. Clin. Pathol. 101, 166-176 (1994).
26. Bartlett JMS, Langdon SP, Simpson BJB et al. The prognostic value of epidermal growth factor receptor MRNA expression in primary ovarian cancer. Br. J. Cancer 73, 301-306 (1996).
27. Kristensen GB, Holm R, Abeler VM et al. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor and c-ErbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 78, 433-434 (1996).
28. Iihara K, Shiozaki H, Tahara H et al. Prognostic significance of transforming growth factor-α in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer 71, 2902-2909 (1993).
29. Shin DM, Donato NJ, Perez-Soler R et al. Epidermal growth factor receptor-targeted therapy with humanized chimeric monoclonal antibody, C225, in combination with cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7(5), 1204-1213 (2001).
30. Grandis JR, Melhem MF, Barnes EL et al. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78, 1284-1292 (1996).
31. Shin DM, Ro JY, Hong WK et al. Dysregulation of epidermal growth factor receptor expression in multistep process of head and neck tumorigenesis. Cancer Res. 54, 3153-3159 (1994).
32. Klijn JG, Berns PMJ, Schmitz PIM et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr. Rev. 13, 3-17 (1992).
33. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res. Treat. 53, 167-176 (1999).
34. Bucci B, D'Agnano I, Botti C et al. EGFR expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res 17, 769-774 (1997).
35. Volm M, Rittgen W, Drings P. Prognostic value of ErbB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br. J. Cancer 77, 663-669 (1998).
36. Pavelic K, Banjac Z, Pavelic J et al. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 13, 1133-1137 (1993).
37. Fujino S, Enokibori T, Tezuka N et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur. J. Cancer 32A, 2070-2074 (1996).
38. Rusch V, Klimstra D, Venkatraman E et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor-α is frequent in resectable non-small cell lung cancer but does not predict tumor progressions. Clin. Cancer Res. 3, 515-522 (1997).
39. Fontanini G, De Laurentiis M, Vignati S et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected Stage I-IIIA non-small cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res. 4, 241-249 (1998).
40. Brabender J, Danenberg K, Metzger R et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer. Res. 7, 1850-1855 (2001).
41. Messa C, Russo F, Caruso MG et al. EGF, TGF-α and EGFR in human colorectal adenocarcinoma. Acta. Oncol. 37, 285-289 (1998).
42. Mayer A, Takimoto M, Fritz E et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and MDR gene expression in colorectal cancer. Cancer 71, 2454-2460 (1993).
43. Fischer-Colbrie J, Witt A, Heinzl H et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res. 17, 613-623 (1997).
44. Niikura H, Sasano H, Sato S et al. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int. J. Gynecol. Pathol. 16, 60-68 (1997).
45. Chow NH, Liu HS, Lee EI et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 17, 1293-1296 (1997).
46. Turkeri LN, Erton ML, Cevik I et al. Impact of the expression of epidermal growth factor, transforming growth factor-α and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology 51, 645-649 (1998).
47. Koullias GJ, Kouraklis GP, Raftopoulos IS et al. Increased estrogen receptor and epidermal growth factor receptor gene product co-expression in surgically resected gastric adenocarcinomas. J. Surg. Oncol. 63, 166-171 (1996).
48. Ekstrand AJ, James CD, Cavanee WK et al. Genes for epidermal growth factor receptor, transforming growth factor-α and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51, 2164-2172 (1991).
49. Solorzano C, Baker C, Tsan R et al. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin. Cancer Res. 7, 2563-2572 (2001).
50. Moyer JD, Barbacci EG, Iwata KK et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57, 4838-4848 (1997).
51. Chu CT, Everiss KD, Wikstrand CJ et al. Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J. 324, 855-861 (1997).
52. Stumm G, Eberwein S, Rostock-Wold S et al. Concomitant overexpression of the EGFR and ErbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int. J. Cancer 69, 17-22 (1996).
53. Wikstrand CJ, Hale LP, Batra SK et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55, 3140-3148 (1995).
54. Chu CT, Everiss KD, Wikstrand CJ et al. Receptor dimerization is not a factor in the signaling activity of a transforming variant epidermal growth factor (EGFRvIII). Biochem. J. 324, 855-861 (1997).
55. Olapade-Olaopa EO, Moscatello DK, MacKay EH et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br. J. Cancer 82, 186-194 (2000).
56. Wikstrand CJ, McLendon RE, Friedman AH et al. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 57, 4130-4140 (1997).
57. Grandis JR, Melhem MF, Gooding WE et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 90, 824-832 (1998).
58. Prewett M, Rockwell RF, Rockwell P et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunother. 19, 419-427 (1996).
59. Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anticancer therapy. Pharmacol. Ther. 64, 127-154 (1994).
60. Mendelsohn J, Baselga J. Antibodies to growth factors and receptors. Biol. Ther. Cancer 607-623 (1995).
61. Modjtahedi H, Dean C. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Int. J. Oncol. 4, 277-296 (1994).
62. Modjtahedi H, Styles JM, Dean CJ. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br. J. Cancer 67, 247-253 (1993).
63. Modjtahedi H, Eccles S, Box G et al. Immunotherapy of human tumor xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br. J. Cancer 67, 254-261 (1993).
64. Sato JD, Kawamoto T, Le AD et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1, 511-529 (1983).
65. Fan Z, Mendelsohn J, Masui H et al. Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies. J. Biol. Chem. 268, 21073-21079 (1993).
66. Fan Z, Lu Y, Wu X et al. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem. 269, 27595-27602 (1994).
67. Goldstein NI, Prewett M, Zuklys K et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1, 1311-1318 (1995).
68. Chou J-L, Fan Z, DeBlasio T et al. Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res. Treat. 55, 267-283 (1999).
69. Markowitz SD, Molkentin K, Gerbic C et al. Growth stimulation by coexpression of transforming growth factor-α and epidermal growth factor receptor in normal and adenomatous human colon epithelium. J. Clin. Investig. 86, 365-362 (1990).
70. Perrotte P, Matsumoto T, Inoue K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5, 257-265 (1999).
71. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59, 1935-1940 (1999).
72. Mandal M, Adam L, Mendelsohn J et al. Nuclear targeting of BAX during epidermal growth factor receptor-induced apoptosis in colorectal cancer cells. Oncogene 17, 999-1007 (1998).
73. Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and ERB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151, 1523-1530 (1997).
74. Bruns CJ, Harbison MT, Davis DW et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by anti-angiogenic mechanisms. Clin. Cancer Res. 6, 1936-1948 (2000).
75. Naramura M, Gillies SD, Mendelsohn J et al. Therapeutic potential of chimeric and murine anti-epidermal growth factor receptor antibodies in a metastasis model for human melanoma. Cancer Immunol. Immunother. 37, 343-349 (1993).
76. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy - the fourth annual Joseph H Burchenal American association for Cancer Research, clinical research award lecture. Clin. Cancer Res. 6, 747-753 (2000).
77. Fan Z, Masui H, Atlas I et al. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 53, 4322-4328 (1993).
78. Baselga J, Norton L, Masui H et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl Cancer Inst. 85, 1327-1333 (1993).
79. Fan Z, Baselga J, Masui H et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53, 4637-4642 (1993).
80. Ciardiello F, Bianco R, Damiano V et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. 5, 909-916 (1999).
81. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18, 904-914 (2000).
82. Gunnett K, Motzer R, Amato R et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody C225 alone in patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. 389 (1999) (Abstract 19).
83. Huag SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis. Clin. Cancer Res. 6, 2166-2174 (2000).
84. Ezekiel MP, Bonner JA, Robert F. Phase I trial of chimerized epidermal growth factor receptor (EGFR) antibody in combination with once-daily or twice-daily irradiation for locally advanced head and neck malignancies. Proc. Am. Soc. Clin. Oncol. (1999) (Abstract 1501).
85. Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann. Oncol. 11(Suppl. 13), 187-190 (2000).
86. Perez-Soler R, Donato N, Shin D et al. Tumor epidermal growth factor receptor studies in patients with non-small cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852. J. Clin. Oncol. 12, 730-739 (1994).
87. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18, 904-914 (2000).
88. Crombet-Ramos T, Torres L, Salano M. Pharmacological and clinical evaluation of the humanized antiEGFR monoclonal antibody h-R3 in patients with advanced epithelial carcinomas. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 1012).
89. Yang XD, Jia XC, Corvalan J et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236-1243 (1999).
90. Figlin RA, Belldegrun A, Lohner ME. ABX-EGF: a fully humanized antiEGF receptor antibody in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 1102).
91. Modjtahedi H, Hickish T, Nicolson M et al. Phase I trial and tumor localization of the antiEGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br. J. Cancer 73, 228-235 (1996).
92. Hoffman T, Hafner D, Ballo H et al. Antitumor activity of antiepidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 17, 4419-4426 (1997).
93. Stragliotto G, Vega F, Stasiecki P et al. Multiple infusions of antiepidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55900) in patients with recurrent malignant gliomas. Eur. J. Cancer 32A, 636-640 (1996).
94. Sartor C. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Semin. Oncol. (In Press).
95. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst. 89, 341-343 (1997).
96. Radke K, Gilmore T, Martin GS. Transformation by Rous sarcoma virus: a cellular substrate for transformation specific protein phosphorylation contains phosphotyrosine. Cell 21, 821-828 (1980).
97. Macias A, Azavedo E, Hagerstrom T et al. Prognostic significance of the receptor for epidermal growth factor receptor in human mammary cancers. Anticancer Res. 7, 459-64 (1987).
98. Akiyama T, Saito T, Ogawara H et al. Tumor promoter and epidermal growth factor stimulate phosphorylation of the c-ErbB-2 gene product in MKN-7 human adenocarcinoma cells. Mol. Cell. Biol. 8, 1019-1926 (1988).
99. Fava R, Cohen S. Isolation of a calcium-dependent 35-kDa substrate for the epidermal growth factor receptor/kinase from A-431 cells. J. Biol. Chem. 259, 2636-2645 (1984).
100. Haigler HT, Schlaepfer DD, Burgess WH. Characterization of lipocortin I and an immunologically unrelated 33-kDa protein as epidermal growth factor receptor/kinase substrate and phospholipase A2 inhibitors. J. Bio. Chem. 262, 6921-6930 (1987).
101. Fry DW, Kraker AJ, McMichael A et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265, 1093-1095 (1994).
102. Karnes WE, Weller SG, Adjei PN et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology 114, 930-939 (1998).
103. He Y, Zeng Q, Drenning SD et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J. Natl Cancer Inst. 90, 1080-1087 (1998).
104. Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol. Ther. 82, 207-218 (1999).
105. Zaman GJ, Vink PM, Van den Doelen AA et al. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor β-receptor (β-PDGFR) and discovery of a novel inhibition of receptor tyrosine kinases. Biochem. Pharmacol. 57, 57-64 (1999)
106. Smaill JB, Palmer BD, Rewcastle GW et al. Tyrosine kinase inhibitors: 15,4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibition of the ATP binding site of the epidermal growth factor receptor. J. Med. Chem 42, 1803-1815 (1999).
107. Showalter HD, Bridget AJ, Zhou H et al. Tyrosine kinase inhibitors 16,6,5,6-tricyclic benzothieno3,2-dpyrimidines and pyrimido5,4-b- and -4,5- bindoles as potent inhibitions of epidermal growth factor receptor tyrosine kinase. J. Med. Chem. 42, 5464-5474 (1999).
108. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59, 753-767 (2000).
109. Ghosh S, Zheng Y, Jun X et al. α-cyano-β-hydroxy-β-methy-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. Clin. Cancer Res. 4, 2657-2668 (1998).
110. Sudbeck EA, Liu XP, Narla RK et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res. 5, 1569-1582 (1999).
111. Lane HA, Beuvink I, Motoyama AB et al. ERB-B2 potentiates breast tumor proliferation through modulation of p27 (KIP1)-CDK2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol. 20, 3210-3223 (2000).
112. Woodburn JR, Barker AJ, Gibson KH et al. ZD-1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc. Am. Assoc. Cancer Res. (1997) (Abstract 4251).
113. Sirotnak F, Zakowski M, Liller V et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (IRESSA), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6, 4885-4892 (2000).
114. Woodburn JR, Kendrew J, Fennell M et al. ZD-1839 (IRESSA), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): inhibition of c-FOS mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition. Proc. Am. Assoc. Cancer Res. (2000) (Abstract 2552).
115. Cardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (IRESSA), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053-2063 (2000).
116. Ciardiello F, Damiano V, Bianco R et al. Inhibition of EGFR-tyrosine kinase by ZD1839 (IRESSA) leads to antiproliferative and anti-angiogenic effects in human GEO colon cancer xenografts in combination with paclitaxel. Proc. Am. Assoc. Cancer Res. (2001) (Abstract 4580).
117. Normanno N, Campiglio M, De Luca A et al. Co-operative inhibitory effect of ZD1839 (IRESSA) in combination with trastuzumab on human breast cancer cell growth. Proc. Am. Assoc. Cancer Res. (2001) (Abstract 4156).
118. Baselga J, Herbst R, LoRusso P et al. Continuous administration of ZD-1839 (IRESSA), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types: evidence of activity and good tolerability. Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 686).
119. Negoro S, Nakagawa K, Fukuoka M et al. Final results of a Phase I intermittent dose-escalation trial of ZD 1839 (IRESSA®) in Japanese patients with various solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 1292).
120. Noonberg S, Benz C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs 59, 753-767 (2000).
121. Bianco R, Yakes FM, Mills GB et al. EGF receptor-overexpressing tumor cells that lack PTEN/MMAC1 and RB are resistant to small molecule EGFR kinase inhibitors. Proc. Am. Assoc. Cancer Res. (2001) (Abstract 4567).
122. Pollack V, Savage D, Baker D et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. JPET 291, 739-748 (1999).
123. Iwata K, Miller PE, Barbacci EG et al. CP-358,774: a selective EGFR tyrosine kinase inhibitor with potent antiproliferative activity against head and neck tumor cells. Proc. Am. Assoc. Cancer Res. (1997) (Abstract 4248).
124. Senzer NN, Soulieres D, Siu L et al. Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 6).
125. Perez-Soler R, Chachoua A, Huberman M et al. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients with advanced, EGFR expressing, non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 1235).
126. Bos M, Mendelsohn J, Kim YM et al. PD-153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin. Cancer Res. 3, 2099-2106 (1997).
127. Nguyen DM, Chen A, Stewart JH et al. Sensitization of esophageal cancer cells expressing high levels of epidermal growth factor receptor (EGFR) to chemotherapy (CT) or irradiation (Ir) by the EGFR-specific tyrosine kinase inhibitor PD-153035. Proc. Am. Assoc. Cancer Res. (2001) (Abstract 4568).
128. Fry DW, Bridges AJ, Denny WA et al. Specific, irreversible inactivation of the epidermal growth factor receptor and ErbB2, by new class of tyrosine kinase inhibitor. Proc. Natl Acad. Sci. USA 95, 12022-12027 (1998).
129. Bruns C, Solorzano C, Harbison M et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60, 2926-2935 (2000).
130. Lackey K, Affleck K, Allen P et al. The discovery of the new anticancer agent GW2016: a potent dual EGFR/ErbB-2 tyrosine kinase inhibitor. Proc. Am. Assoc. Cancer Res. (2001) (Abstract 4582).
131. Traxler PM, Furet P, Mett H et al. 4-(phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 39, 2285-2292 (1996).
132. Traxler P, Bold G, Frei J et al. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. J. Med. Chem. 40, 3601-3616 (1997).
133. Grandis JR, Chakraboty A, Zeng Q et al. Downmodulation of TGF-α protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J. Cell. Biochem. 69, 55-62 (1998).
134. He Y, Zeng Q, Drenning SD et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J. Natl Cancer Inst. 90, 1080-1087 (1998).
135. Fry DW, Nelson JM, McMichael A et al. Specific suppression of the epidermal growth factor receptor tyrosine kinase in tumor cells and ensuing inhibition of clone formation in soft agar. Proc. Am. Assoc. Cancer Res. (1996) (Abstract 2893).
136. Fry DW, Nelson JM, Slintak V et al. Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem. Pharmacol. 54, 877-887 (1997).
137. Patmore SJ, Roberts BJ, Stoner CL et al. In vivo evaluation of the irreversible EGF receptor tyrosine kinase inhibitor PD 168393. Proc. Am. Assoc. Cancer Res. 560 (1998) (Abstract 39).
138. Garrison M, Tolcher A, McCreery H. A Phase I and pharmacokinetic study of CI-1033, a pan-ErbB tyrosine kinase inhibitor, given orally on day 1, 8 and 15 every 28 days to patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 283).
139. Shin DM, Nemunaitis J, Zinner RG et al. A Phase I clinical and biomarker study of CI-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 324).
140. Modjahedi H, Affleck K, Stubberfield C et al. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int. J. Oncol. 13, 335-342 (1998).